Literature DB >> 19028363

Adult-onset Still disease.

Bruno Fautrel1.   

Abstract

Adult-onset Still disease (AOSD) is an uncommon inflammatory condition of unknown origin typically characterized by four main (cardinal) symptoms: spiking fever > or =39 degrees C, arthralgia or arthritis, skin rash and hyperleucocytosis (> or =10,000 cells/mm3) with neutrophils > or =80%. As many other manifestations are possible, diagnosis is potentially challenging. Determination of the total and glycosylated ferritin levels, although not pathognomonic, can help in diagnosis. The disease evolution of AOSD can be monocyclic, polycyclic or chronic. In chronic disease, joint involvement is often predominant and erosions are noted in one-third of patients. No prognostic factors have been identified to date. Therapeutic strategies are from observational data. Corticosteroids are usually the first-line treatment. With inadequate response to corticosteroids, methotrexate appears the best choice to control disease activity and allow for tapering of steroid use. For refractory disease, biological therapy with agents blocking interleukin-1 (anakinra) and then those blocking interleukin-6 (tocilizumab) seem the most promising.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028363     DOI: 10.1016/j.berh.2008.08.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  72 in total

1.  Therapeutic responses and prognosis in adult-onset Still's disease.

Authors:  Hyoun-Ah Kim; Jun-Mo Sung; Chang-Hee Suh
Journal:  Rheumatol Int       Date:  2011-01-29       Impact factor: 2.631

2.  A rare case of severe acute hepatitis associated with adult-onset still disease dramatically improved by high-dose steroid therapy.

Authors:  Tiffany Hogan; Kevin T Kao; Jim Tung
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

Review 3.  A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.

Authors:  Katja Perdan-Pirkmajer; Sonja Praprotnik; Matija Tomšič
Journal:  Clin Rheumatol       Date:  2010-08-24       Impact factor: 2.980

4.  A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?

Authors:  Francesca Dall'Ara; Micol Frassi; Angela Tincani; Paolo Airò
Journal:  Clin Rheumatol       Date:  2016-01-12       Impact factor: 2.980

5.  Towards explaining "unexplained hyperferritinemia".

Authors:  Clara Camaschella; Erika Poggiali
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

6.  A case of adult-onset Still's disease complicated with atypical pulmonary defect.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2009-10-07       Impact factor: 2.631

7.  Serum growth arrest-specific protein 6 levels are elevated in adult-onset Still's disease.

Authors:  Hyoun-Ah Kim; Jin-Young Nam; Ju-Yang Jung; Chang-Bum Bae; Jeong-Mi An; Ja-Young Jeon; Bong-Sik Kim; Chang-Hee Suh
Journal:  Clin Rheumatol       Date:  2014-04-27       Impact factor: 2.980

8.  A case of uveitis in adult-onset Still's disease with ophthalmologic symptoms.

Authors:  Wenmin Jiang; Luosheng Tang; Xuanchu Duan; Bing Jiang
Journal:  Rheumatol Int       Date:  2011-12-31       Impact factor: 2.631

9.  Adult-Onset Still's Disease: A Case Report.

Authors:  Ong Ping Seung; Wahinuddin Sulaiman
Journal:  Oman Med J       Date:  2011-09

10.  Application of Fluorine-18-Deoxyglucose Positron Emission Tomography and Gallium Scan for Assessment in a Patient With Adult-Onset Still's Disease.

Authors:  Jing-Uei Hou; Shih-Chuan Tsai; Wan-Yu Lin
Journal:  Arch Rheumatol       Date:  2016-04-13       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.